Skip to main content

Table 1. New strategies in first-line treatment for ovarian cancer

From: Ovarian cancer standard of care: are there real alternatives?

Strategy Trial Number of patients Stage Armsa Primary endpoint Results
NACT EORTC55971[19] 670 IIIC–IV PS → CP × 6 OS (non inferiority) IDS is not inferior to PS (30 vs. 29 months, HR = 0.98, 90% CI = 0.84 to 1.13, P = 0.01)
CP × 3 → IDS→CP × 3
  CHORUS trial[20] 550 IIIC–IV PS → CP × 6 OS (non inferiority) IDS is not inferior to PS (24.5 vs. 22.8 months, HR = 0.87, 80% CI, 0.76 to 0.98)
CP × 3→IDS→CP × 3
IP CHT GOG172[22] 429 III PS → IPCisP × 6 PFS and OS Prolonged PFS (23.8 vs. 18.3 months, P = 0.05) and prolonged OS (65.6 vs. 49.7 months, P = 0.03)
PS → IVCisP × 6
  GOG114[23] 462 III PS, IVC→ IVP, IPCis × 6 PFS and OS Prolonged PFS (27.9 vs. 22.2 months, P = 0.01) and prolonged OS (63.2 vs. 52.2 months, P = 0.05)
PS → IVCisP × 6
DD CHT JGOG 3016[30,31] 637 II–IV 3weeCP × 6 PFS and OS Prolonged PFS (28 vs. 17.2 months, P = 0.015) and prolonged OS (100 vs. 62 months, P = 0.039)
3weeC+ wP × 6
  MITO-7[32] 822 IC–IV 3weeCP × 6 QoL and PFS Better QoL for wCP (P < 0.001) but no benefit in PFS (17.3 vs. 18.3 months, P = 0.66)
wCP × 6
  GOG262[36] 692 II–IV 3weeCP × 6 PFS Prolonged PFS (only without bevacizumab, HR = 0.97)
3weeBCP × 6→Bm
3weeC+ wP × 6
3weeC+ wP →Bm
New doublets SCOTROC 1[37] 1,077 IC–IV CP × 6 PFS No benefit in PFS (14.8 vs. 15.0 months, P = 0.707)
CD × 6
  MITO-2[39] 820 IC–IV CP × 6 PFS No benefit in PFS (16.8 vs. 19.0 months, P = 0.58)
C-LPD × 6
  1. a “x n” means “for n cycles of chemotherapy.” NACT: neoadjuvant chemotherapy; PS: primary surgery; CP: carboplatin plus paclitaxel; IDS: interval debulking surgery; HR: hazard ratio; CI: confidence interval; OS: overall survival; IP CHT: intraperitoneal chemotherapy; IPCisP: intraperitoneal cisplatin 100 mg/m2 on day 1 plus intraperitoneal paclitaxel 60 mg/m2 on day 8 every 3 weeks; IVCisP: intravenous cisplatin 75 mg/m2 on day 1 plus intravenous paclitaxel 135 mg/m2 on day 2 every 3 weeks; PFS: progression-free survival; IVC: intravenous carboplatin AUC 9 mg/mL per minute for 2 cycles every 28 days; IVP: intravenous paclitaxel 135 mg/m2 on day 1 every 3 weeks; IPCis: intraperitoneal cisplatin 100 mg/m2 on day 2 every 3 weeks; DD CHT: dose-dense; 3weeCP: 3 weekly carboplatin plus paclitaxel; 3weeC: 3 weekly carboplatin; wP: weekly paclitaxel; wCP: weekly carboplatin plus paclitaxel; QoL: quality of life; 3weeBCP: 3 weekly carboplatin plus paclitaxel plus bevacizumab; Bm: bevacizumab maintenance; CD: carboplatin AUC 5 mg/mL per minute plus docetaxel 75 mg/m2; C-LPD: carboplatin AUC 5 mg/mL per minute plus pegylated-liposomal-doxorubicin 30 mg/m2 every 3 weeks.